Dubai Creates Longevity Authority for Advanced Health

Dubai has created a dedicated Longevity Authority to regulate and grow one of the world’s fastest-emerging health sectors, placing wellness, advanced healthcare and life-enhancing therapies under a new specialised government mandate.

His Highness Sheikh Mohammed bin Rashid Al Maktoum issued Law No. (17) of 2026 on June 9, 2026, establishing the Dubai Longevity Authority, known as DLA. Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, has been appointed President of the authority under Decree No. (14) of 2026, while Helal Saeed Almarri, Director General of the Dubai Department of Economy and Tourism, has been appointed Chairman under Decree No. (15) of 2026.

A new regulator for a growing health economy

The Dubai Longevity Authority has been set up with a clear mandate: position Dubai as a global hub for regulated longevity, wellness and advanced healthcare services. That wording matters. The authority is not being presented as a promotional council or a narrow health office, but as a regulator and market builder for a sector that touches medicine, consumer wellness, scientific research and clinical delivery.

Longevity has moved well beyond the language of lifestyle. In Dubai’s model, it sits at the intersection of research and development, clinical trials, manufacturing, patient clinics and advanced therapeutic products. The creation of a single authority gives the emirate a focal point for areas that often sit across several government and private-sector domains.

Sheikh Mohammed has framed the move around investment in people’s health and quality of life, with Dubai aiming to lead in healthcare innovation to enhance human health. That gives the DLA a broader social purpose as well as an economic one: it is expected to support the emirate’s ambition to improve how long people live well, not simply how healthcare products are sold.

What the authority will oversee

DLA will establish a science-driven regulatory framework covering the full chain of the longevity and advanced health sector. The scope includes research and development, clinical trials, manufacturing, delivery and patient clinics. In practice, that means the authority is expected to shape the rules for how new services and products are developed, tested, produced and delivered in Dubai.

The framework will also cover a sophisticated market for advanced therapeutic products and services. The official mandate points to breakthrough therapies that extend lifespan and healthspan, placing the emphasis on both length of life and quality of life. For a city that has spent years building health, tourism and business infrastructure, the new authority gives this specialist field its own regulatory pathway.

The authority will work with Dubai Health Authority, Dubai Health, Dubai Municipality and Dubai Future Foundation to ensure compliance with international standards. That collaboration is important because longevity is not a single discipline. It can involve clinical regulation, health services, municipal oversight, future technologies and investment strategy. DLA’s role is to connect those areas without diluting standards.

The brief is ambitious, but not yet operationally detailed. Specifics on the DLA’s internal structure, first projects and implementation timelines have not been disclosed. For businesses and clinicians, the next phase will be defined by how the authority translates its mandate into licensing pathways, compliance requirements and sector priorities.

Leadership and Dubai’s wider agenda

The appointments put the new authority close to Dubai’s central economic and social priorities. Sheikh Hamdan’s role as President signals senior leadership oversight, while Helal Saeed Almarri’s appointment as Chairman links the authority directly with Dubai’s economy and tourism leadership. That combination reflects the dual nature of the sector: it is about healthcare outcomes, but also about attracting talent, companies and investment.

DLA supports the Dubai Economic Agenda D33 and the Dubai Social Agenda 33. Those agendas include the aim of positioning Dubai among the top three cities globally for quality of life and achieving a leading position in healthy life expectancy. The authority therefore sits inside a wider city strategy, not as a standalone health initiative.

Dubai’s target is clear: rank among the top three cities globally for quality of life and secure a leading position in healthy life expectancy.

Helal Saeed Almarri has highlighted the rapid growth of the longevity, wellness and advanced health sector, as well as Dubai’s commitment to capturing opportunities in the field. That business framing is central to the DLA. The authority is designed to help Dubai compete for a sector where regulation, credibility and scientific standards will be as important as commercial speed.

Why investors, founders and talent will watch closely

For founders, the most important signal is that Dubai wants this sector to be regulated from the start. Longevity and advanced health services can attract ambitious companies, but the market also depends on trust. A science-driven framework gives serious operators a clearer basis for building, while giving the government a mechanism to keep standards aligned with international expectations.

DLA has been tasked with attracting international investment and talent, fostering innovation and nurturing top talent to advance medicine, wellness and transformative life-enhancing technologies. That creates a business angle beyond clinics alone. The opportunity spans research teams, health technology companies, therapeutic product developers, wellness operators and service providers that can meet regulatory expectations.

Dubai’s pitch to investors is likely to rest on coordination. The authority’s planned collaboration with Dubai Health Authority, Dubai Health, Dubai Municipality and Dubai Future Foundation suggests a model where health governance, public services, municipal oversight and future-focused innovation are brought into one strategic orbit. For companies entering a sensitive sector, that kind of coordination can matter as much as market demand.

There is also a clear tourism and services dimension, given Almarri’s role at the Dubai Department of Economy and Tourism. The research brief does not disclose specific programmes, incentives or commercial targets, but the leadership structure shows that the sector is being treated as part of Dubai’s broader economic positioning. The city is not only asking how advanced health services should be regulated; it is asking how they can become a credible part of its future economy.

What comes next for Dubai’s longevity push

The immediate question is execution. Law No. (17) of 2026 establishes the DLA, and the leadership decrees set its top table. What has not yet been announced is the authority’s operational structure, its initial projects or the timelines for its first initiatives. Those details will determine how quickly companies, clinics, researchers and investors can engage with the new framework.

The sequencing matters. A sector that spans clinical trials, manufacturing and patient clinics cannot be built on branding alone. It needs rules that companies can understand, standards that patients can trust and coordination between public authorities. Dubai’s decision to create a dedicated authority suggests it wants to define the market before the market defines itself.

For residents, the long-term promise sits in quality of life and healthy life expectancy. For businesses, the near-term focus will be on licensing clarity, permitted activities, compliance standards and the kinds of advanced therapeutic products and services the authority prioritises. For the city, the test will be whether DLA can make Dubai a place where longevity companies can build responsibly at scale.

The next announcements from the Dubai Longevity Authority will be watched for the details that turn a bold legal mandate into a working market.